Application of genomics to drug design:: the example of the histamine H3 receptor

被引:16
|
作者
Schwartz, JC
Morisset, S
Rouleau, A
Tardivel-Lacombe, J
Gbahou, F
Ligneau, X
Héron, A
Sasse, A
Stark, H
Schunack, W
Ganellin, RC
Arrang, JM
机构
[1] INSERM, U109, Unite Neurobiol & Pharmacol Mol, Ctr Paul Broca, F-75014 Paris, France
[2] Lab Bioprojet, F-75002 Paris, France
[3] Fac Sci Pharmaceut & Biol Paris, Lab Physiol, F-75006 Paris, France
[4] Free Univ Berlin, Inst Pharm, D-14195 Berlin, Germany
[5] UCL, Dept Chem, London WC1 H0AJ, England
关键词
histaminergic systems; H(3) autoreceptor; constitutive activity; inverse agonists;
D O I
10.1016/S0924-977X(01)00121-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The histamine H(3) receptor was characterized in the 1980s as an autoreceptor regulating histamine release in brain. Since then, selective drugs have been designed, many of them displaying a high potency in vivo, and used in many studies to delineate the implications of cerebral histaminergic systems in physiological functions such as arousal or cognitive functions. The recent cloning of the H(3) receptor, more than 15 years later, has allowed to start molecular studies that led to important findings for optimization of drug design. In agreement some ligands display distinct affinities for the recombinant rat and human H3 receptors, a difference that we assign to two amino acids in the third transmembrane domain. In addition, H(3) autoreceptors present in the brain display high constitutive activity including in vivo. As a consequence, inverse agonists enhance histamine neuron activity and constitute a novel potential therapeutic approach to schizophrenia and Alzheimer's disease. (C) 2001 Elsevier Science BY All rights reserved.
引用
收藏
页码:441 / 448
页数:8
相关论文
共 50 条
  • [1] Histamine H3 Receptor as a Drug Discovery Target
    Berlin, Michael
    Boyce, Christopher W.
    Ruiz, Manuel de Lera
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (01) : 26 - 53
  • [2] The histamine H3 receptor: molecular pharmacology and therapeutic application
    Schwartz, J. -C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 1 - 1
  • [3] Histamine H3 receptor agonists
    De Esch, IJP
    Belzar, KJ
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (09) : 955 - 963
  • [4] Histamine H3 receptor antagonists
    Tozer, MJ
    Kalindjian, SB
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (07) : 1045 - 1055
  • [5] Therapeutic implications of constitutive activity of receptors:: the example of the histamine H3 receptor
    Schwartz, JC
    Morisset, S
    Rouleau, A
    Ligneau, X
    Gbahou, F
    Tardivel-Lacombe, J
    Stark, H
    Schunack, W
    Ganellin, CR
    Arrang, JM
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2003, (64): : 1 - 16
  • [6] The histamine H3 receptor as a therapeutic drug target for CNS disorders
    Gemkow, Mark J.
    Davenport, Adam J.
    Harich, Silke
    Ellenbroek, Bart A.
    Cesura, Andrea
    Hallett, David
    DRUG DISCOVERY TODAY, 2009, 14 (9-10) : 509 - 515
  • [7] The histamine H3 receptor: from gene cloning to H3 receptor drugs
    Rob Leurs
    Remko A. Bakker
    Henk Timmerman
    Iwan J. P. de Esch
    Nature Reviews Drug Discovery, 2005, 4 : 107 - 120
  • [8] The histamine H3 receptor:: From gene cloning to H3 receptor drugs
    Leurs, R
    Bakker, RA
    Timmerman, H
    de Esch, IJP
    NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (02) : 107 - U18
  • [9] DESIGN OF MULTITARGETING HISTAMINE H3 RECEPTOR ANTAGONISTS FOR NEURODEGENERATIVE DISEASES
    Hagenow, S.
    Stasiak, A.
    Bautista-Aguilera, O.
    Palomino-Antolin, A.
    Farre-Alins, V.
    Jimeno, M. L.
    Martinez, A. Romero
    Lopez-Munoz, F.
    Iriepa, I.
    Moraled, I.
    Soukop, O.
    Janockova, J.
    Ismaili, L.
    Kalinowsky, L.
    Proschak, E.
    Schwed, J. S.
    Chioua, M.
    Egea, J.
    Marco-Contelles, J.
    Joffrin, P. -J.
    Ramsay, R. R.
    Stark, H.
    INFLAMMATION RESEARCH, 2018, 67 : S13 - S13
  • [10] Constitutive activity of the histamine H3 receptor
    Arrang, Jean-Michel
    Morisset, Severine
    Gbahou, Florence
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (07) : 350 - 357